Skip to main content

Table 1 Clinical characteristics, therapeutic data and outcomes of the five patients

From: High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

Patient Gender Age Histopathology Ann Arbor Stage Primary refractorya Lines of chemo before IT PD-L1 inhibitor PD-1 inhibitor OS Status
Cycle Response Duration Cycle Responseb Duration
1 M 24y NSHL IVA Yes 3 + Rad 8 PD 3 m 13 CR 28 m 72 m Alive
2 F 36y NSHL IVB Yes 3 + Rad 4 PD 3 m 12 CR 28 m 46 m Alive
3 F 54y NSHL IIA Yes 4 + Rad 4 PD 3 m - - - 46 m Dead
4 F 43y MCHL IIA Yes 7 6 PD 4 m 6 CR 18 m 72 m Alive
5 M 33y NSHL IVA Yes 2 8 PD 5 m 11 PR 26 m 46 m Alive
  1. Abbreviation: OS = overall survival; F = female; M = male; NSHL = nodular sclerosing Hodgkin lymphoma; MCHL = mixed cellularity Hodgkin lymphoma; IT = immunotherapy; Rad = radiation; CR = complete response; PR = partial response; PD = progressive disease
  2. aPrimary refractory was defined as end-of-treatment positron emission tomography-computed tomography (PET-CT) scan positive
  3. bPatient 1, 2 and 4 were in CR, patient 5 was in PR at the last assessment